PTSD
Posttraumatic stress disorder (PTSD) is a significant mental health challenge affecting over 354 million individuals globally. Psychedelics, particularly MDMA and psilocybin, are emerging as promising therapeutic options, offering new avenues for treatment through innovative psychotherapeutic interventions.
Key Insights
- 1
MDMA-assisted therapy has demonstrated very large effects, with 56% of participants no longer meeting PTSD criteria in early trials.
- 2
The majority of participants in MDMA trials were war veterans, a demographic which shows higher PTSD prevalence compared to the general population.
- 3
Ketamine shows promise in reducing PTSD symptoms, but results are mixed, with some studies indicating limited dosage effects and transient benefits.
- 4
Mescaline remains under-researched in PTSD treatment, but user surveys suggest potential symptom improvement.
- 5
Psychedelics like MDMA may 'reopen' critical periods for emotional processing, facilitating therapeutic breakthroughs.
What is PTSD?
Posttraumatic stress disorder (PTSD) is a psychiatric condition that arises following a traumatic event, including natural disasters, violence, war, and sexual assault. The disorder is characterised by a range of symptoms grouped into four categories: intrusive memories, avoidance behaviours, negative changes in cognition and mood, and alterations in emotional and physical responses.
Common symptoms include distressing recollections of the traumatic experience, avoidance of reminders, negative self-perception, heightened startle response, and emotional numbing. To be diagnosed with PTSD, a person must exhibit symptoms persisting for more than one month, which disrupt daily functioning.
Current Treatments
Standard treatment for PTSD often combines psychotherapy (including cognitive processing therapy and prolonged exposure therapy) with pharmacotherapy, predominantly SSRIs such as paroxetine and sertraline. Anxiolytics may be used short-term, but they carry an abuse risk.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for PTSD.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| MDMA Strong evidence from multiple Phase II and Phase III trials shows substantial efficacy in treating PTSD. | Large | High | Consistent |
| Ketamine Initial positive trials indicate efficacy but larger studies yield mixed results. | Medium | Moderate | Inconsistent |
| Psilocybin Emerging research suggests potential benefits, but more rigorous studies are needed. | Small | Low | Inconsistent |
| Mescaline Limited surveys suggest anecdotal benefits without controlled trials. | Small | Very Low | Inconsistent |
MDMA and PTSD
MDMA is classified as an entactogen, which promotes feelings of emotional openness and empathy—critical for processing traumatic experiences. It functions primarily by increasing serotonin levels, thereby enhancing emotional fluidity during therapeutic sessions. This heightened state of receptiveness enables therapeutic breakthroughs as individuals confront and reframe their traumatic memories with the guidance of a trained therapist.
Ketamine and PTSD
Ketamine acts as an NMDA receptor antagonist, leading to an increase in glutamate levels which may stimulate synaptogenesis and enhance neural activity. This mechanism is theorised to alleviate depressive symptoms associated with PTSD, although the lack of structured therapy in studies complicates the understanding of its efficacy specifically for PTSD treatment.
Clinical Outlook
The future of psychedelic treatment for PTSD appears promising as ongoing research unfolds, particularly with MDMA likely to receive regulatory approval soon. Continued collaboration between research institutions and private companies may lead to more comprehensive and effective treatment paradigms for PTSD sufferers, although rigorous clinical trials remain imperative to establish safety and efficacy.
Industrial Landscape
Key players in this field include MAPS (Multidisciplinary Association for Psychedelic Studies), which has been pivotal in advancing MDMA therapy; Numinus, focusing on therapeutic psychedelic applications; and Seelos Therapeutics, working on ketamine formulation. Non-profits such as Healing Breakthrough and Remedy are also instrumental in research and clinical applications for PTSD.
Quick Indicators
Organisations
Search →Ohio State University
The Ohio State University is a public land-grant research university based in Columbus, Ohio, offering undergraduate, graduate, and professional programs and conducting research across many fields. It was founded as the Ohio Agricultural and Mechanical College and serves as a major educational and economic institution in Ohio.
COMPASS Pathways
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
Delix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
METIV Israel Psychotrauma Center
The METIV Israel Psychotrauma Center is a leading authority in trauma treatment and research. The center is involved in exploring MDMA-assisted therapy for PTSD, aligning with a broader mission to develop advanced treatment methods for trauma-related conditions exacerbated by conflict.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
Resilient Pharmaceuticals
Resilient Pharmaceuticals (formerly Lykos Therapeutics, formerly MAPS PBC) is a US-based public benefit corporation developing MDMA-assisted therapy for PTSD. It was founded in 2014 by MAPS (Multidisciplinary Association for Psychedelic Studies) as a commercial spinout to carry MAPS’ three decades of MDMA research through late-stage trials and regulatory approval. After completing two Phase 3 trials and filing an NDA in 2024, the FDA issued a Complete Response Letter (CRL) in August 2024, citing concerns about functional unblinding, durability of response, safety reporting at two trial sites, and the challenge of blinding psychedelic studies. The CRL requested a third Phase 3 trial. Following the rejection, the company laid off approximately 75% of staff. In May 2025, billionaire investors Antonio Gracias (Gracias Foundation) and Sir Christopher Hohn (TCI Fund) led a $50 million Series B recapitalisation, installing new leadership: CEO Mike Burke and CMO Javier Muniz. Rick Doblin, MAPS’ founder, remains supportive of the new direction. The company rebranded from Lykos Therapeutics to Resilient Pharmaceuticals on 28 August 2025, and continues to negotiate a path to FDA approval for MDMA-assisted therapy for PTSD.
AtaiBeckley
Clinical-stage psychedelic company that also functions as a strategic-corporate capital allocator through legacy atai platform investments and deal activity in the sector.
MAPS
Nonprofit organizer and host of the Psychedelic Science conference series, alongside broader educational and policy programming.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Ketamine Research Institute
The Ketamine Research Institute is a US-based clinical research organization developing precision medicine approaches to ketamine infusion therapy, studying optimized dosing protocols to treat depression and offering clinician training in evidence-based ketamine practice.
University of California, San Francisco
University of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.
University of Sydney
The Brain and Mind Centre is advancing psychedelic science with a multidisciplinary focus on developing innovative treatments using AI and preparing for human clinical trials to treat severe mental illness.
People
Search →Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Eduardo Schenberg
Neuroscientist and founder/director of Instituto Phaneros
A leading Brazilian psychedelic researcher known for clinical and translational work on ayahuasca, ibogaine, MDMA, and ethics/policy in psychedelic medicine.
Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Aaron Klaiber
Doctoral researcher at the University of Basel
He appears as an author on multiple controlled human psychedelic studies spanning DMT, mescaline, MDMA, LSD, and psilocybin, suggesting a substantial role in contemporary psychopharmacology research.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Juliana Rocha
Doutoranda em Ciências Médicas / Saúde Mental at the Ribeirão Preto Medical School, University of São Paulo
She is a recurring coauthor on clinical psychedelic studies, especially ayahuasca trials on social anxiety, emotion recognition, personality, and social cognition, helping expand the human evidence base for psychedelic-assisted psychiatric research.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Michiel Van Elk
Associate Professor of Cognitive Psychology at Leiden University
Michiel van Elk is a prominent psychedelic science researcher known for rigorous, skeptical work on psilocybin, microdosing, expectancy effects, and the psychological mechanisms and risks of psychedelic experiences.
Jolien Veraart
Psychiatrist and PhD researcher at the University Medical Center Groningen / University of Groningen
She is a leading clinical researcher on ketamine and oral esketamine for treatment-resistant depression, including safety, efficacy, and real-world implementation.
Philippe Lucas
Director, Research and Safe Access at MAPS
He is a prominent Canadian psychedelic and cannabis researcher whose work has helped establish early evidence on ayahuasca-assisted therapy, psychedelic survey research, and harm-reduction policy.
Connected Evidence
The latest clinical data and verified academic findings associated with PTSD.